Loading...

APC anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Pricing & Availability
Clone
RB6-8C5 (See other available formats)
Regulatory Status
RUO
Other Names
Gr-1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
Rb6-8C5_APC_Ly-6GslashLy-6C_Antibody_1_FC_090116
C57BL/6 mouse bone marrow stained with Ly-6G/Ly-6C APC (clone RB6-8C5, filled histogram) or APC Rat IgG2b, κ isotype control (open histogram).
  • Rb6-8C5_APC_Ly-6GslashLy-6C_Antibody_1_FC_090116
    C57BL/6 mouse bone marrow stained with Ly-6G/Ly-6C APC (clone RB6-8C5, filled histogram) or APC Rat IgG2b, κ isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Save
108411 25 µg ¥6,160
108412 100 µg ¥17,560
Description

Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Raised against granulocytes of mouse origin
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References

(PubMed link indicates BioLegend citation)
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
  2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
  6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
  8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
  9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
  11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
  13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
  14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
  15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
  16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
  17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
  18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
  19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
  24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
  26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
  30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
  31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
  32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
  34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
  35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
Product Citations
  1. Gerlach BD, et al. 2021. Cell Metab. 33:2445. PubMed
  2. Schnell A, et al. 2021. Cell. 184:6281. PubMed
  3. Tan YY, et al. 2022. Bio Protoc. 12:e4307. PubMed
  4. Poh AR, et al. 2022. Sci Adv. 8:eabl7882. PubMed
  5. Zhang Z, et al. 2022. Integr Cancer Ther. 21:15347354221138534. PubMed
  6. Shi C, et al. 2023. Nat Nanotechnol. 18:86. PubMed
  7. Wang D, et al. 2023. J Exp Clin Cancer Res. 42:26. PubMed
  8. Chen Y, et al. 2023. Stem Cells Int. 2023:7482546. PubMed
  9. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  10. Chun J, et al. 2023. Cancers (Basel). 15: . PubMed
  11. Leick MB, et al. 2022. Cancer Cell. 40:494. PubMed
  12. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  13. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  14. Guo H, Cooper S, Friedman A, et al. 2017. PLoS One. 10.1371/journal.pone.0150809. PubMed
  15. Lim H, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.72. PubMed
  16. Haimon Z et al. 2018. Nature immunology. 19(6):636-644 . PubMed
  17. Gan T, et al. 2019. Front Microbiol. 9:3174. PubMed
  18. Tong CF, et al. 2018. Am J Physiol Cell Physiol. 315:C409. PubMed
  19. Dzhagalov I, et al. 2007. Blood . 109:1620. PubMed
  20. Ma X, et al. 2023. Nat Commun. 14:1606. PubMed
  21. He Y, et al. 2023. Biomolecules. 13:. PubMed
  22. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  23. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  24. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  25. Symeonidou V, et al. 2021. Cell Rep. 37:109900. PubMed
  26. Sharma GP, et al. 2021. PLoS One. 16:e0259042. PubMed
  27. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  28. Gonalves S, et al. 2021. Cell Reports. 34(11):108860. PubMed
  29. Kim JS, et al. 2020. Immunity. 54(1):176-190.e7. PubMed
  30. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  31. Jaiswal AK, et al. 2020. Immunobiology. 225:151956. PubMed
  32. Kaku H, et al. 2014. J Immunol. 193:5904. PubMed
  33. Zhou W, et al. 2019. Cell Syst. 0.597916667. PubMed
  34. Mollaoglu G et al. 2018. Immunity. 49(4):764-779 . PubMed
  35. Götz P, et al. 2022. Int J Mol Sci. 23:. PubMed
  36. Ma C, et al. 2012. J Leukoc Biol. 92:1199. PubMed
  37. Zhu H, et al. 2018. Elife. 7:. PubMed
  38. Yu VWC et al. 2016. Cell. 167(5):1310-1322 . PubMed
  39. Hinterbrandner M, et al. 2021. JCI Insight. 6:e151797. PubMed
  40. Gu T, et al. 2021. Front Immunol. 11:621441. PubMed
  41. Yuan Q, et al. 2021. Cell Reports. 34(5):108724. PubMed
  42. Zhao J, et al. 2020. Pharmacol Res Perspect. 8:e00660. PubMed
  43. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  44. Han Y, et al. 2020. Nat Commun. 11:1776. PubMed
  45. Agelidis A, et al. 2019. Front Immunol. 10:500. PubMed
  46. Sun Y et al. 2018. Cancer cell. 34(4):643-658 . PubMed
  47. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  48. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  49. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  50. Mann M, et al. 2018. Cell Rep. 25:2992. PubMed
  51. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  52. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  53. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  54. Konishi H, et al. 2020. EMBO J. 39:e104464. PubMed
  55. Vannini N, et al. 2019. Cell Stem Cell. 24:405. PubMed
  56. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  57. Tamura M, et al. 2019. Sci Rep. 9:8171. PubMed
  58. Gunn BM et al. 2018. Cell host & microbe. 24(2):221-233 . PubMed
  59. Voisin M, et al. 2021. Commun Biol. 4:420. PubMed
  60. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  61. Koujah L, et al. 2021. Ocul Surf. 21:238. PubMed
  62. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  63. Distel E, et al. 2014. Circ Res . 115:759. PubMed
  64. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  65. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  66. Parada-Kusz M, et al. 2018. Dis Model Mech. 11:. PubMed
  67. Zeng J, et al. 2019. Cell Rep. 27:549. PubMed
  68. Chen D, et al. 2020. Cancer Immunol Res. 8:883. PubMed
  69. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  70. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  71. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  72. Yu VWC, et al. 2017. Cell. 168:944. PubMed
  73. Abraham TS, et al. 2019. J Immunol. 202:1301. PubMed
  74. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  75. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  76. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  77. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  78. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  79. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  80. Tavakol DN, et al. 2021. Curr Protoc. 1:e275. PubMed
  81. Mansell E, et al. 2020. Cell Stem Cell. . PubMed
  82. Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed
  83. Mishra BB, et al. 2017. Nat Microbiol. 2:17072. PubMed
  84. Kumar MP, et al. 2018. Cell Rep. 25:1458. PubMed
  85. Booth CAG, et al. 2018. Cancer Cell. 33:274. PubMed
  86. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  87. Cho K, et al. 2021. iScience. 24:103117. PubMed
  88. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  89. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  90. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  91. Galle-Treger L, et al. 2020. J Allergy Clin Immunol. 145:502. PubMed
  92. Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed
  93. Agelidis A, et al. 2021. JCI Insight. 6: . PubMed
  94. Chen X, et al. 2016. PLoS One. 11:e0168861. PubMed
  95. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  96. Jonas B, et al. 2016. PLoS One. 11: 0159189. PubMed
  97. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  98. Korrer M, Routes J 2014. PLoS One. 9:91370. PubMed
  99. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  100. Sydney Lavoie et al. 2019. eLife. 8 pii: e39982. PubMed
  101. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  102. Xiao Y, et al. 2022. Nat Commun. 13:758. PubMed
  103. Guan X, et al. 2022. Nat Commun. 13:2834. PubMed
  104. Yang C, et al. 2016. Sci Rep. 6:34643. PubMed
  105. Gao Y, et al. 2020. Immunity. 52(6):1007-1021.e8. PubMed
  106. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  107. Ha TC, et al. 2020. Hum Gene Ther. 32:458. PubMed
  108. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  109. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  110. Ouyang L, et al. 2016. Sci Rep. 6:39541. PubMed
  111. Lu W, et al. 2016. PLoS One. 11: 0149543. PubMed
  112. Winchell CG, et al. 2020. Front Immunol. 1.077083333. PubMed
  113. Yu JM, et al. 2019. Nat Commun. 4.388888889. PubMed
  114. Okwan–Duodu D, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1125. PubMed
  115. Metidji A et al. 2018. Immunity. 49(2):353-362 . PubMed
  116. Tuong ZK, et al. 2021. Cell Rep. 37:110132. PubMed
  117. Kandasamy M, et al. 2013. PLoS Pathog. 9:e1003115. PubMed
  118. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  119. Ruscher R, et al. 2018. Bio Protoc. 8:e2757. PubMed
  120. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  121. Ovadya Y, et al. 2018. Nat Commun. 9:5435. PubMed
  122. Di Genua C, et al. 2019. Haematologica. 104:2215. PubMed
  123. Siddique SM, et al. 2019. Sci Rep. 9:13977. PubMed
  124. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  125. Pattabiraman D, et al. 2009. Mol Cancer Res. 1.317361111. PubMed
  126. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  127. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  128. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  129. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  130. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  131. Skucha A, et al. 2018. Nat Commun. 9:1983. PubMed
  132. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  133. Hu R, et al. 2015. J Immunol. 195: 4802 - 4809. PubMed
  134. Asada S, et al. 2018. Nat Commun. 9:2733. PubMed
  135. Weckbach LT, et al. 2019. J Exp Med. 216:350. PubMed
  136. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  137. Nguyen GT, et al. 2020. eLife. 9:e56656.. PubMed
  138. Matsumoto M, et al. 2008. J Immunol. 181:3628. PubMed
  139. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  140. Fielding C, et al. 2022. Nat Commun. 13:543. PubMed
  141. Kurashima Y, et al. 2021. Nat Commun. 12:1067. PubMed
  142. Iwai H, et al. 2015. Tuberculosis (Edinb). 95:246. PubMed
  143. Qiu X, et al. 2009. Infect Immun. 77:85. PubMed
  144. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  145. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  146. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  147. Collins C, et al. 2014. Proc Natl Acad Sci U S A. 111:9899. PubMed
  148. Hussein M, et al. 2015. PLoS One. 10: 0135218. PubMed
  149. Vannini N, et al. 2016. Nat Commun. 7:13125. PubMed
  150. Stone S et al. 2018. Glia. 66(7):1331-1345 . PubMed
  151. Schmidts A, et al. 2020. J Immunother Cancer. 8:. PubMed
  152. Wang Y, et al. 2022. Nat Cell Biol. 24:230. PubMed
  153. Zhang J, et al. 2021. Stem Cell Res Ther. 12:579. PubMed
  154. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  155. Zeng F, et al. 2021. J Invest Dermatol. 596:141. PubMed
  156. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  157. Cabal-Hierro L, et al. 2020. Nat Commun. 11:1406. PubMed
  158. Omenetti S, et al. 2019. Immunity. 51:77. PubMed
  159. Wang X, et al. 2018. Front Immunol. 9:2615. PubMed
  160. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
RRID
AB_313376 (BioLegend Cat. No. 108411)
AB_313376 (BioLegend Cat. No. 108412)

Antigen Details

Structure
21-25 kD
Distribution

Granulocytes, monocytes

Cell Type
Granulocytes, Monocytes, Neutrophils
Biology Area
Immunology, Innate Immunity
Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID
17067 View all products for this Gene ID 546644 View all products for this Gene ID
UniProt
View information about Ly-6G Ly-6C on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All Ly-6G/Ly-6C Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
FITC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE/Cyanine5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
PE/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC
Alexa Fluor® 647 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,SB
Alexa Fluor® 700 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 711™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Pacific Blue™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 421™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 570™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Ultra-LEAF™ Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IP,CMCD,Depletion,IHC,WB
Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 605™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 650™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 IHC-F,FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) (Maxpar® Ready) RB6-8C5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 750 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
TotalSeq™-A0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-C0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-B0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
Spark Blue™ 550 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 810 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Violet™ 423 anti-mouse Ly-6G/Ly-6C (GR-1) Antibody RB6-8C5 FC
Spark UV™ 387 anti-mouse Ly-6G/Ly-6C (GR-1) RB6-8C5 FC
Spark Violet™ 538 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark PLUS UV395™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Red™ 718 anti-mouse Ly-6G/Ly-6C (Gr-1) (Flexi-Fluor™) RB6-8C5 FC
Spark Blue™ 574 anti-mouse Ly-6G/Ly-6C (Gr-1) (Flexi-Fluor™) RB6-8C5 FC
Go To Top Version: 3    Revision Date: 09/01/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account